How does the ketogenic diet work? Four potential mechanisms

Journal of Child Neurology

Volumn 28, Issue 8, 2013, Pages 1027-1033

  Danial, Nika N ^a   Hartman, Adam L ^b   Stafstrom, Carl E ^c   Thio, Liu Lin ^d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ATP sensitive K channel; epilepsy; glucose; ketogenic diet; mammalian target of rapamycin; mechanism of action; Seizure; vesicular glutamate transporters

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; MAMMALIAN TARGET OF RAPAMYCIN;

CARBOHYDRATE INTAKE; CONFERENCE PAPER; EPILEPSY; HUMAN; KETOGENIC DIET; MITOCHONDRIAL RESPIRATION; MOLECULAR MECHANICS; PRIORITY JOURNAL; SYNAPTIC TRANSMISSION;

EID: 84879699812     PISSN: 08830738     EISSN: 17088283     Source Type: Journal    
DOI: 10.1177/0883073813487598     Document Type: Conference Paper

References (70)

1. Levy RG, Cooper PN, Giri P.. Ketogenic diet and other dietary treatments for epilepsy. Cochrane Database Syst Rev. 2012 ; 3: CD001903
2. Kossoff EH, Zupec-Kania BA, Amark PE, et al. Optimal clinical management of children receiving the ketogenic diet: recommendations of the International Ketogenic Diet Study Group. Epilepsia. 2009 ; 50: 304-317
3. Stafstrom CE, Rho JM. The ketogenic diet as a treatment paradigm for diverse neurological disorders. Front Pharmacol. 2012 ; 3: 59
4. Seyfried BT, Kiebish M, Marsh J, Mukherjee P. Targeting energy metabolism in brain cancer through calorie restriction and the ketogenic diet. J Cancer Res Ther. 2009 ; 5 (S1). S7 - S15
5. Poplawski MM, Mastaitis JW, Isoda F, et al. Reversal of diabetic nephropathy by a ketogenic diet. PLoS One. 2011 ; 6: e18604
6. Huttenlocher PR.. Ketonemia and seizures: Metabolic and anticonvulsant effects of two ketogenic diets in childhood epilepsy. Pediatr Res. 1976 ; 10: 536-540
7. Stafstrom CE, Roopra A, Sutula TP. Seizure suppression via glycolysis inhibition with 2-deoxy-d-glucose. Epilepsia. 2008 ; 49 (S8). 97-100
8. Zhao M, Nguyen J, Ma H, et al. Preictal and ictal neurovascular and metabolic coupling surrounding a seizure focus. J Neurosci. 2011 ; 31: 13292-13300
9. Garriga-Canut M, Schoenike B, Qazi R, et al. 2-Deoxy-d-glucose reduces epilepsy progression by NRSF-CtBP-dependent metabolic regulation of chromatin structure. Nat Neurosci. 2006 ; 9: 1382-1387
10. Stafstrom CE, Ockuly JC, Murphree L, et al. Anticonvulsant and antiepileptic actions of 2-deoxy-d-glucose in epilepsy models. Ann Neurol. 2009 ; 65: 435-447
11. Lian X-Y, Khan FA, Stringer JL.. Fructose-1,6-biphosphate has anticonvulsant activity in models of acute seizures in adult rats. J Neurosci. 2007 ; 27: 12007-12011
12. Gasior M, Yankura J, Hartman AL, et al. Anticonvulsant and proconvulsant actions of 2-deoxy-d-glucose. Epilepsia. 2010 ; 5: 1385-1394
13. He XP, Kotloski R, Nef S, et al. Conditional deletion of TrkB but not BDNF prevents epileptogenesis in the kindling model. Neuron. 2004 ; 43: 31-42
14. Huang YZ, McNamara JO. Inhibiting glycolysis to reduce seizures: how it might work. Nat Neurosci. 2006 ; 9: 1351-1352
15. Hu XL, Cheng X, Fei J, Xiong ZQ. Neuron-restrictive silencer factor is not required for the antiepileptic effect of the ketogenic diet. Epilepsia. 2011 ; 52: 1609-1616
16. Pan YZ, Ockuly JC, Rutecki PA, Sutula TP.. Activity-dependent effects of 2DG influencing synaptic transmission, LTP, LTD, and epileptogenesis. Soc Neurosci Abstr. 2008 ;: 147
17. Pan YZ, Devinney MJ, Rutecki PA, Sutula TP. Effect of glycolytic metabolism on synaptic currents in CA3 pyramidal neurons. Soc Neurosci Abstr. 2009 ; 10 (/16). 331
18. Sutula T, Franzoso S. Dose-response and time course of action of disease-modifying effects of 2DG on kindling progression: effectiveness of administration after seizures. Epilepsia. 2008 ; 49 (suppl 7). 382
19. Ockuly JC, Gielissen JM, Levenick CV, et al. Behavioral, cognitive, and safety profile of 2-deoxy-2-glucose (2DG) in adult rats. Epilepsy Res. 2012 ; 101: 246-252
20. Minor RK, Smith DL, Sossong AM, et al. Chronic ingestion of 2-deoxy-d-glucose induces cardiac vacuolization and incre-ases mortality in rats. Toxicol Appl Pharmacol. 2010 ; 243: 332-339
21. Milder J, Patel M. Modulation of oxidative stress and mitochondrial function by the ketogenic diet. Epilepsy Res. 2012 ; 100: 295-303
22. Ma W, Berg J, Yellen G. Ketogenic diet metabolites reduce firing in central neurons by opening K(ATP) channels. J Neurosci. 2007 ; 27: 3618-3625
23. Tanner GR, Lutas A, Martinez-Francois JR, Yellen G. Single K ATP channel opening in response to action potential firing in mouse dentate granule neurons. J Neurosci. 2011 ; 31: 8689-8696
24. Danial NN. BAD: undertaker by night, candyman by day. Oncogene. 2008 ; 27 (suppl 1). S53 - S70
25. Gimenez-Cassina A, Martinez-Francois JR, Fisher JK, et al. BAD-dependent regulation of fuel metabolism and K(ATP) channel activity confers resistance to epileptic seizures. Neuron. 2012 ; 74: 719-730
26. Laplante M, Sabatini DM.. mTOR signaling at a glance. J Cell Sci. 2009 ; 122 (pt 20). 3589-3594
27. Tang SJ, Reis G, Kang H, et al. A rapamycin-sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus. Proc Natl Acad Sci U S A. 2002 ; 99: 467-472
28. Hou L, Klann E. Activation of the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin signaling pathway is required for metabotropic glutamate receptor-dependent long-term depression. J Neurosci. 2004 ; 24: 6352-6361
29. Orlova KA, Crino PB. The tuberous sclerosis complex. Ann N Y Acad Sci. 2010 ; 1184: 87-105
30. Zeng LH, Xu L, Gutmann DH, Wong M. Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann Neurol. 2008 ; 63: 444-453
31. Zeng LH, Rensing NR, Zhang B, et al. Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex. Hum Mol Genet. 2011 ; 20: 445-454
32. Ljungberg MC, Sunnen CN, Lugo JN, et al. Rapamycin suppresses seizures and neuronal hypertrophy in a mouse model of cortical dysplasia. Dis Model Mech. 2009 ; 2: 389-398
33. Sunnen CN, Brewster AL, Lugo JN, et al. Inhibition of the mammalian target of rapamycin blocks epilepsy progression in NS-Pten conditional knockout mice. Epilepsia. 2011 ; 52: 2065-2075
34. Zeng LH, Rensing NR, Wong M. The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy. J Neurosci. 2009 ; 29: 6964-6972
35. Huang X, Zhang H, Yang J, et al. Pharmacological inhibition of the mammalian target of rapamycin pathway suppresses acquired epilepsy. Neurobiol Dis. 2010 ; 40: 193-199
36. Talos DM, Sun H, Zhou X, et al. The interaction between early life epilepsy and autistic-like behavioral consequences: a role for the mammalian target of rapamycin (mTOR) pathway. PLoS One. 2012 ; 7: e35885
37. Raffo E, Coppola A, Ono T, et al. A pulse rapamycin therapy for infantile spasms and associated cognitive decline. Neurobiol Dis. 2011 ; 43: 322-329
38. Buckmaster PS, Lew FH. Rapamycin suppresses mossy fiber sprouting but not seizure frequency in a mouse model of temporal lobe epilepsy. J Neurosci. 2011 ; 31: 2337-2347
39. Huang X, McMahon J, Yang J, et al. Rapamycin down-regulates KCC2 expression and increases seizure susceptibility to convulsants in immature rats. Neuroscience. 2012 ; 219: 33-47
40. Sliwa A, Plucinska G, Bednarczyk J, Lukasiuk K. Post-treatment with rapamycin does not prevent epileptogenesis in the amygdala stimulation model of temporal lobe epilepsy. Neurosci Lett. 2012 ; 509: 105-109
41. Krueger DA, Care MM, Holland K, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med. 2010 ; 363: 1801-1811
42. Hartman AL, Santos P, Dolce A, Hardwick JM. The mTOR inhibitor rapamycin has limited acute anticonvulsant effects in mice. PLoS One. 2012 ; 7: e45156
43. Ruegg S, Baybis M, Juul H, et al. Effects of rapamycin on gene expression, morphology, and electrophysiological properties of rat hippocampal neurons. Epilepsy Res. 2007 ; 77: 85-92
44. Raab-Graham KF, Haddick PC, Jan YN, Jan LY. Activity- and mTOR-dependent suppression of Kv1.1 channel mRNA translation in dendrites. Science. 2006 ; 314: 144-148
45. Jaworski J, Spangler S, Seeburg DP, et al. Control of dendritic arborization by the phosphoinositide-3′-kinase-Akt-mammalian target of rapamycin pathway. J Neurosci. 2005 ; 25: 11300-11312
46. Weston MC, Chen H, Swann JW.. Multiple roles for mammalian target of rapamycin signaling in both glutamatergic and GABAergic synaptic transmission. J Neurosci. 2012 ; 32: 11441-11452
47. Terashima A, Nakai M, Hashimoto T, et al. Single-channel activity of the Ca2+-dependent K+ channel is modulated by FK506 and rapamycin. Brain Res. 1998 ; 786: 255-258
48. Wang Y, Barbaro MF, Baraban SC. A role for the mTOR pathway in surface expression of AMPA receptors. Neurosci Lett. 2006 ; 401: 35-39
49. Ho VM, Lee JA, Martin KC. The cell biology of synaptic plasticity. Science. 2011 ; 334: 623-628
50. McDaniel SS, Rensing NR, Thio LL, et al. The ketogenic diet inhibits the mammalian target of rapamycin (mTOR) pathway. Epilepsia. 2011 ; 52: e7 - e11
51. Hartman AL, Lyle M, Rogawski MA, Gasior M. Efficacy of the ketogenic diet in the 6-Hz seizure test. Epilepsia. 2008 ; 49: 334-339
52. Gilbert DL, Pyzik PL, Freeman JM. The ketogenic diet: seizure control correlates better with serum beta-hydroxybutyrate than with urine ketones. J Child Neurol. 2000 ; 15: 787-790
53. Ross DL, Swaiman KF, Torres F, Hansen J. Early biochemical and EEG correlates of the ketogenic diet in children with atypical absence epilepsy. Pediatr Neurol. 1985 ; 1: 104-108
54. Fraser DD, Whiting S, Andrew RD, et al. Elevated polyunsaturated fatty acids in blood serum obtained from children on the ketogenic diet. Neurology. 2003 ; 60: 1026-1029
55. Neal EG, Chaffe H, Schwartz RH, et al. A randomized trial of classical and medium-chain triglyceride ketogenic diets in the treatment of childhood epilepsy. Epilepsia. 2009 ; 50: 1109-1117
56. Muzykewicz DA, Lyczkowski DA, Memon N, et al. Efficacy, safety, and tolerability of the low glycemic index treatment in pediatric epilepsy. Epilepsia. 2009 ; 50: 1118-1126
57. Kang HC, Lee HS, You SJ, et al. Use of a modified Atkins diet in intractable childhood epilepsy. Epilepsia. 2007 ; 48: 182-186
58. Kossoff EH, McGrogan JR, Bluml RM, et al. A modified Atkins diet is effective for the treatment of intractable pediatric epilepsy. Epilepsia. 2006 ; 47: 421-424
59. van Delft R, Lambrechts D, Verschuure P, et al. Blood beta-hydroxybutyrate correlates better with seizure reduction due to ketogenic diet than do ketones in the urine. Seizure. 2010 ; 19: 36-39
60. Bough KJ, Eagles DA. A ketogenic diet increases the resistance to pentylenetetrazole-induced seizures in the rat. Epilepsia. 1999 ; 40: 138-143
61. Bough KJ, Valiyil R, Han FT, Eagles DA. Seizure resistance is dependent upon age and calorie restriction in rats fed a ketogenic diet. Epilepsy Res. 1999 ; 35: 21-28
62. Likhodii SS, Musa K, Mendonca A, et al. Dietary fat, ketosis, and seizure resistance in rats on the ketogenic diet. Epilepsia. 2000 ; 41: 1400-1410
63. Nylen K, Likhodii S, Abdelmalik PA, et al. A comparison of the ability of a 4:1 ketogenic diet and a 6.3:1 ketogenic diet to elevate seizure thresholds in adult and young rats. Epilepsia. 2005 ; 46: 1198-1204
64. Raffo E, Francois J, Ferrandon A, et al. Calorie-restricted ketogenic diet increases thresholds to all patterns of pentylenetetrazol-induced seizures: critical importance of electroclinical assessment. Epilepsia. 2008 ; 49: 320-328
65. Keith HM. Factors influencing experimentally produced convulsions. Arch Neurol Psychiatry. 1933 ; 29: 148-154
66. Likhodii SS, Serbanescu I, Cortez MA, et al. Anticonvulsant properties of acetone, a brain ketone elevated by the ketogenic diet. Ann Neurol. 2003 ; 54: 219-226
67. Gasior M, French A, Joy MT, et al. The anticonvulsant activity of acetone, the major ketone body in the ketogenic diet, is not dependent on its metabolites acetol, 1,2-propanediol, methylglyoxal, or pyruvic acid. Epilepsia. 2007 ; 48: 793-800
68. Donevan SD, White HS, Anderson GD, Rho JM. Voltage-dependent block of N-methyl-d-aspartate receptors by the novel anticonvulsant dibenzylamine, a bioactive constituent of l-(+)-beta-hydroxybutyrate. Epilepsia. 2003 ; 44: 1274-1279
69. Thio LL, Wong M, Yamada KA. Ketone bodies do not directly alter excitatory or inhibitory hippocampal synaptic transmission. Neurology. 2000 ; 54: 325-331
70. Juge N, Gray JA, Omote H, et al. Metabolic control of vesicular glutamate transport and release. Neuron. 2010 ; 68: 99-112